Butt JH, Nicolau JC, Verma S, et al. - In patients with heart failure (HF) with reduced ejection fraction (HFrEF) enrolled in the Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure trial (DAPA‐HF), the efficacy and safety of dapagliflozin vs placebo were examined according to etiology. Etiology was categorized as ischaemic or non‐ischaemic. Randomization of a total of 4,744 patients was done in DAPA‐HF, of whom 2,674 (56.4%) patients had an ischaemic etiology. Per outcomes, patients with ischaemic and non‐ischaemic etiology show similarly decreased risk of worsening HF and death, and have similar improvement in symptoms when provided dapagliflozin. Furthermore, dapagliflozin is identified as safe and is well‐tolerated, irrespective of etiology.